Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain Stimulation
GALWAY, Ireland, Aug. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter (Q1) of fiscal year 2025 (FY25), which ended July 26, 2024.
Key Highlights
Revenue of $7.9 billion, adjusted revenue of $8.0 billion, increased 2.8% as reported and 5.3% organicGAAP diluted earnings per share (EPS) of $0.80; non-GAAP diluted EPS of $1.23Company increases FY25 organic revenue growth and EPS guidanceMultiple franchises deliv